Cardialysis is a leading niche provider, specialized in cardiology offering the full range of clinical research services around fast-track, high-quality development of medical devices, pharmaceutical products and combinations in all phases of clinical research. Our processes are compliant with Good Clinical Practice (GCP), guidelines of the European Medicines Agency (EMA), the Food and Drug Administration (FDA), the International Conference on Harmonization (ICH) and with ISO standards.
Cardialysis is headquartered in Rotterdam, The Netherlands, and has global reach through its monitoring network in Western and Eastern European countries and via a network of preferred CRO partners outside Europe. Through our network of over 1400 clinical sites monitored by local CRAs with experience in cardiovascular trials, Cardialysis has access to a large number of potential trial participants.
The company has a track record of over 400 clinical trials including landmark trials that contributed to major advances in cardiology over the past decades and to the approval of drugs and devices currently used in every-day practice around the world.
Mission and Vision
It is our mission to be @ the heart of cardiovascular research serving the interests of our clients i.e., our global network of collaborating cardiology professionals, industries and regulators. This, in order to continuously pursue improvements in patient care. We achieve this by offering a continuously improved state-of-the-art full-service infrastructure for the design and conduct of smart trials with the world’s most promising innovations.
Cardialysis was incepted in 1983 by cardiologists from the Thorax Center of the Erasmus Medical Center in Rotterdam, the Netherlands; the medical center that still plays a prominent role in the expanding international faculty that surrounds Cardialysis today. From a small Holter data analysis unit in the early eighties, Cardialysis has developed into an internationally recognized independent cardiovascular research organization, collaborating with major scientific, medical device and pharmaceutical partners from around the world. Nowadays, Cardialysis has a long, diversified track record and is one of the leading organizations in the field.